



Janssen COVID-19 Vaccine – CDC updates recommendation

- On December 16, 2021, the Centers for Disease Control and Prevention's (CDC) [Advisory Committee for Immunization Practices \(ACIP\) met](#) to vote on updated recommendations for use of the Janssen COVID-19 vaccine.
- The ACIP voted unanimously in favor of a statement indicating that mRNA COVID-19 vaccines are clinically preferred over Janssen's COVID-19 vaccine to prevent COVID-19 among people aged 18 years and older.
- The [CDC presented](#) information from the Vaccine Adverse Event Reporting System (VAERS) on 54 cases of thrombosis with thrombocytopenia syndrome (TTS) following vaccination with a single dose of the Janssen vaccine between March 2 and August 31, 2021.
 - Overall, 3.83 TTS cases were reported per million doses.
 - The highest rates of TTS occurred among women aged 30 - 39 years (n = 11; 10.6 cases per million) and among women aged 40 - 49 years (n = 10; 9.02 cases per million).
 - All the patients were hospitalized with nine patients discharged to post-acute care facilities, 37 discharged home, and eight dying in the hospital.
 - One additional patient died after August 31, 2021.
- The CDC director [approved this recommendation](#) shortly after the meeting.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.